Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cystic Fibrosis: early-phase trial registry
49 of 170 indexed Cystic Fibrosis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #64 of 28,707 conditions by registered trial count.
170 US clinical trials · 49 currently recruiting · #64 of 28,707 conditions by registered trial count
Cystic Fibrosis: 170 US clinical trials tracked, 49 recruiting.
Cystic Fibrosis is the subject of 170 registered US clinical trials on ClinicalTrials.gov, 49 of them currently open to new participants. 34 are in Phase 3-4 (later-stage) and 61 in Phase 1-2 (earlier-stage). The most active sponsor is Vertex Pharmaceuticals Incorporated, running 20 of these trials.
Enrollment posture brief
Registry condition cystic-fibrosis
OPEN 49 | RECR 29% | LATE 34 | EARLY 61 | RANK #64 | SPON 20
Volume-matched condition peers
Nearest open-share peer: Prostatic Neoplasms (29% recruiting · 66 trials)
Cystic Fibrosis lists 49 open slots (29% of 170 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Cystic Fibrosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Cystic Fibrosis is recruiting below its size-band peers.
49 of 170 indexed trials (28.8%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Cystic Fibrosis trials is spread across many organizations.
Vertex Pharmaceuticals Incorporated accounts for 20 of 170 trials (11.8%). 84 distinct sponsors appear on at least one study for this condition label.
-
Most Cystic Fibrosis trials plan to enrol fewer than 100 people.
Median target enrolment is 59 among the 170 trials that report a genuine target (sentinel values excluded). 107 of those (62.9%) plan for fewer than 100 participants.
-
Cystic Fibrosis research is mostly interventional.
121 interventional and 49 observational studies make up this index (71.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
170 total, page 3 of 4
Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation
Vertex Pharmaceuticals Incorporated
NCT00865904
A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis Exacerbations
NovaBiotics
NCT03000348
Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients
Savara
NCT01746095
A Prospective, Multicenter, Collaborative Study to Determine the Prevalence of Nontuberculous Mycobacteria (NTM) in Pediatric Patients With Cystic Fibrosis in Florida
University of Miami
NCT02198079
A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis
Vertex Pharmaceuticals Incorporated
NCT02951195
Behavioral & Nutritional Treatment to Help CF Preschoolers Grow
Children's Hospital Medical Center, Cincinnati
NCT00241969
A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis
Vertex Pharmaceuticals Incorporated
NCT03911713
Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis
InterMune
NCT00043316
To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration
AstraZeneca
NCT02679729
Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Vertex Pharmaceuticals Incorporated
NCT01897233
Association of Transcutaneous Pulse CO-oximetry With Inflammatory Lung Diseases
Boston Children's Hospital
NCT02831348
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation
Vertex Pharmaceuticals Incorporated
NCT02725567
Muscle Accrual and Function in Cystic Fibrosis-Impact of Glucose Intolerance
Children's Hospital of Philadelphia
NCT02776098
The Carrier Rates of Pseudomonas Aeruginosa in Family Members of Children With Cystic Fibrosis
Zafer Soultan
NCT01616862
A Decentralized Study to Evaluate Physical Activity and Cough Frequency Using Wearable Technology in Cystic Fibrosis
Vertex Pharmaceuticals Incorporated
NCT04923464
BioEnergetics and Metabolomics in Cystic Fibrosis
Emory University
NCT02225899
Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy Subjects
Vertex Pharmaceuticals Incorporated
NCT01216046
Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease
Vertex Pharmaceuticals Incorporated
NCT02390219
Evaluation of Regional Ventilation Using 19F MRI of Inert Perfluorinated Gases Mixed With Oxygen
Hal C Charles
NCT01710449
Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis
Sanofi
NCT03375047
19F MRI to Evaluate Regional Ventilation in Healthy Subjects and Subjects With Cystic Fibrosis
University of North Carolina, Chapel Hill
NCT03489590
Technology-enabled Patient Support System for Self-management of CF
University of Alabama at Birmingham
NCT03910881
Phase II Study of Growth Hormone in Children With Cystic Fibrosis
University of Utah
NCT00016445
Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic Fibrosis
Amgen
NCT00503490
Safety Study of Inhaled 552-02 in Cystic Fibrosis Patients
Parion Sciences
NCT00274313
A Study to Compare US Marketed Creon Manufactured With a Modernized Process at an Alternate Manufacturing Site and Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
AbbVie
NCT03924947
Safety and Efficacy of Sildenafil in Cystic Fibrosis (CF) Lung Disease
National Jewish Health
NCT00659529
Redox Imbalance and the Development of Cystic Fibrosis Diabetes
Emory University
NCT02202876
Nasal Potential Studies Utilizing Cystic Fibrosis Transmembrane Regulator (CFTR) Modulators
University of Alabama at Birmingham
NCT01348204
MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9)
Nivalis Therapeutics
NCT02934139
Pilot Trial of Phototherapy for Acute Depression in Hospitalized Cystic Fibrosis Patients
Nationwide Children's Hospital
NCT01822197
Inhaled Xylitol Versus Saline in Stable Subjects With Cystic Fibrosis
Joseph Zabner
NCT01355796
Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)
Johns Hopkins University
NCT01594827
Energy Balance and Weight Gain With Ivacaftor Treatment
Children's Hospital of Philadelphia
NCT02141464
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
University of North Carolina, Chapel Hill
NCT01615484
A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)
Boehringer Ingelheim
NCT05865886
FDG-PET Imaging in Young Cystic Fibrosis Patients
Washington University School of Medicine
NCT00846053
Absorptive Clearance in the Cystic Fibrosis Airway
University of Pittsburgh
NCT00541190
Feasibility of Home-based Exercise Program for Adults With Cystic Fibrosis
University of Kansas Medical Center
NCT05239611
Longitudinal Assessment of Exercise Capacity and Vascular Function in Patients With CF
Augusta University
NCT03338595
Hydroxychloroquine in Cystic Fibrosis
Vanderbilt University
NCT00311883
Blood Flow and Vascular Function in Cystic Fibrosis
Augusta University
NCT02057458
Effects of Sildenafil on CFTR-dependent Ion Transport Activity
National Jewish Health
NCT01132482
Telavancin Pharmacokinetics in Cystic Fibrosis Patients
Joseph L. Kuti, PharmD
NCT03172793
Safety and Tolerability of Inhaled Nitric Oxide in Patients With Cystic Fibrosis
Mallinckrodt
NCT00570349
Comparison of Absorption of Vitamin D in Cystic Fibrosis
Emory University
NCT01880346
Comparison of Airway Clearance Therapy in Cystic Fibrosis Using the Same VEST Therapy Device But With Different Settings
University of Minnesota
NCT00685035
Ready to Use Therapeutic Food (RUTF) to Promote Growth in Cystic Fibrosis
Washington University School of Medicine
NCT03462056
Nasally Delivered Pulmozyme for Sinusitis in Cystic Fibrosis
University of Vermont
NCT00416182
Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment
Vertex Pharmaceuticals Incorporated
NCT05437120
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 34 |
| Phase 2 | 27 |
| Phase 3 | 19 |
| Phase 4 | 15 |
Top Sponsors
Named interventions
Most-linked intervention names on Cystic Fibrosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Cystic Fibrosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Cystic Fibrosis page
170 registered trials, 49 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 49 Cystic Fibrosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Vertex Pharmaceuticals Incorporated sponsors the most Cystic Fibrosis trials on record, review their full trial history before evaluating a specific study. See Vertex Pharmaceuticals Incorporated's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cystic Fibrosis condition card totals 170 registered trials; most-linked intervention Placebo; top US site state Colorado. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.